LB Pharmaceuticals director files Form 3

LB PHARMACEUTICALS INC director Robert A. Lenz filed an initial ownership report on Form 3.

Accepted by SEC EDGAR 03/10/2026 - 04:16 PM EDT

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

LB PHARMACEUTICALS INC director Robert A. Lenz filed an initial ownership report on Form 3. This filing establishes his status as a director and formally records his position as an insider of the company, but it does not list any specific share transactions or derivative holdings.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the LB PHARMACEUTICALS (LBRX) Form 3 filing show for Robert A. Lenz?

The Form 3 shows that Robert A. Lenz is a director of LB PHARMACEUTICALS INC. It is an initial insider ownership report and, in this case, does not list any specific transactions or derivative security positions in the structured data.

Does the LBRX Form 3 for Robert A. Lenz report any stock purchases or sales?

No, the Form 3 data for Robert A. Lenz shows no reported purchases, sales, or other transactions. All transaction-related counts, including buys, sells, and exercises, are zero in the transaction summary provided for this filing.

What insider role does Robert A. Lenz have at LB PHARMACEUTICALS INC (LBRX)?

Robert A. Lenz is identified as a director of LB PHARMACEUTICALS INC in the Form 3. He is not reported as an officer and is not classified as a ten percent owner in the structured insider filing data.

Are there any derivative securities reported for Robert A. Lenz in the LBRX Form 3?

No derivative securities are reported for Robert A. Lenz in this Form 3. The derivative summary section is empty and the transaction summary shows zero derivative transactions or option exercises associated with this initial ownership filing.

Does the LB PHARMACEUTICALS (LBRX) Form 3 include any notable footnote disclosures?

The Form 3 includes a footnotes section, but the structured data shows it as blank. There are no additional disclosures about voting power, investment authority, or related entities provided in the available footnote content.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Lenz Robert A.

(Last)

(First)

(Middle)

C/O LB PHARMACEUTICALS INC

ONE PENNSYLVANIA PLAZA, SUITE 1025

(Street)

NEW YORK

10119

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/06/2026

3. Issuer Name and Ticker or Trading Symbol
LB PHARMACEUTICALS INC [ LBRX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)

Explanation of Responses:

No securities are beneficially owned.

	/s/ Marc Panoff, Attorney-in-Fact	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR